November 1st, 2017
View Archives Issues
Dabigatran is an attractive oral anticoagulant for patients who demonstrate indications for oral anticoagulation but are at high risk of bleeding.
A recent meta-analysis of 11 trials showed a significant reduction in all-cause mortality with natriuretic peptide-guided therapy, although the individual trial results varied substantially.
The ATHOS-3 trial represents an important proof of concept trial regarding angiotensin II as a new vasopressor in the armamentarium to treat vasodilatory shock.
Preliminary studies show some promise for use of mindfulness interventions in healthcare practitioners, but the time required for training medical providers in these techniques is identified as a limitation to implementation.